ライフサイエンスコーパス: cardiac arrhythmia

1 heart rate variability could protect against cardiac arrhythmia.

2 tified in patients with Long QT syndrome and cardiac arrhythmia.

3 cardiomyocytes, resulting in a substrate for cardiac arrhythmia.

4 , heart failure, vascular complications, and cardiac arrhythmia.

5 den death syndromes like SUDEP and SIDS, and cardiac arrhythmia.

6 including hypertension, angina pectoris, and cardiac arrhythmia.

7 to reduced muscle performance and to marked cardiac arrhythmia.

8 uences on autonomic outflow, contributing to cardiac arrhythmia.

9 and is associated with an increased risk of cardiac arrhythmia.

10 pilepsy, bipolar disorder, chronic pain, and cardiac arrhythmia.

11 brillation (AF) is the most common sustained cardiac arrhythmia.

12 outcome was life-threatening hypotension or cardiac arrhythmia.

13 imately lead to novel therapeutics targeting cardiac arrhythmia.

14 Atrial fibrillation is the most common cardiac arrhythmia.

15 orm for investigating the basis of reentrant cardiac arrhythmia.

16 the initiation and maintenance of reentrant cardiac arrhythmia.

17 ong-QT syndrome (LQTS), a potentially lethal cardiac arrhythmia.

18 in the elderly group died after surgery from cardiac arrhythmia.

19 ated associations between air pollutants and cardiac arrhythmia.

20 eath, including epileptic encephalopathy and cardiac arrhythmia.

21 ly be developed as therapeutics for LQTS and cardiac arrhythmia.

22 of upd3 is sufficient to block aging-induced cardiac arrhythmia.

23 ential repolarization, which associates with cardiac arrhythmia.

24 to-patient vulnerability in the emergence of cardiac arrhythmia.

25 fibrillation (AF) is the most common type of cardiac arrhythmia.

26 lectrical conduction that may be involved in cardiac arrhythmia.

27 atrial fibrillation (AF), the most frequent cardiac arrhythmia.

28 the ventricular action potential and causes cardiac arrhythmias.

29 nt further investigation in the treatment of cardiac arrhythmias.

30 ges might represent a new strategy to combat cardiac arrhythmias.

31 er the molecular mechanisms and treatment of cardiac arrhythmias.

32 ia reduced fatal severe hypoglycemia-induced cardiac arrhythmias.

33 lcium (Ca(2+)) ions mediate various types of cardiac arrhythmias.

34 festations of triggered activity relevant to cardiac arrhythmias.

35 cardiac repolarization and life-threatening cardiac arrhythmias.

36 modeling observed in patients suffering from cardiac arrhythmias.

37 profiles associated with various (post)ictal cardiac arrhythmias.

38 y artery disease, heart failure, stroke, and cardiac arrhythmias.

39 itable tissues, such as the heart, producing cardiac arrhythmias.

40 ion potential and potentially trigger lethal cardiac arrhythmias.

41 re instrumental in determining mechanisms of cardiac arrhythmias.

42 metallic nanoparticles for the treatment of cardiac arrhythmias.

43 ired long QT syndrome that can lead to fatal cardiac arrhythmias.

44 cation channels and are linked to inherited cardiac arrhythmias.

45 ropensity for spontaneous Ca(2+) release and cardiac arrhythmias.

46 as key players in beta-adrenergic-dependent cardiac arrhythmias.

47 ten a precursor to the initiation of serious cardiac arrhythmias.

48 ADs) are voltage oscillations known to cause cardiac arrhythmias.

49 tes are associated with an increased risk of cardiac arrhythmias.

50 alogs could be developed into drugs to treat cardiac arrhythmias.

51 stress, it can also trigger life-threatening cardiac arrhythmias.

52 athogenesis of heart failure and a number of cardiac arrhythmias.

53 ovel possible mechanism for intermittency of cardiac arrhythmias.

54 hannels within the heart to epilepsy-related cardiac arrhythmias.

55 lonus-dystonia-like syndrome associated with cardiac arrhythmias.

56 fected by a unique dominant M-D syndrome and cardiac arrhythmias.

57 arization, blocking these channels may cause cardiac arrhythmias.

58 and targets for diseases such as cancer and cardiac arrhythmias.

59 ng illness that may lead to heart failure or cardiac arrhythmias.

60 sociated with epilepsy syndromes, autism and cardiac arrhythmias.

61 ) is one of the most severe life-threatening cardiac arrhythmias.

62 ndrome is a long QT interval that results in cardiac arrhythmias.

63 (Cav1) gene variants with increased risk of cardiac arrhythmias.

64 ly afterdepolarizations (EADs) are linked to cardiac arrhythmias.

65 tations resulting in susceptibility to fatal cardiac arrhythmias.

66 eate a substrate favoring the development of cardiac arrhythmias.

67 esulting in impaired contractility and fatal cardiac arrhythmias.

68 ry, myocardial infarction, heart failure and cardiac arrhythmias.

69 al restriction of dietary magnesium increase cardiac arrhythmias.

70 y factors contributing to the development of cardiac arrhythmias.

71 to dysregulation of calcium homeostasis and cardiac arrhythmias.

72 from atrial fibrillation and other types of cardiac arrhythmias.

73 rted to experience higher rates of malignant cardiac arrhythmias.

74 implicated as a driver of potentially lethal cardiac arrhythmias.

75 -gated sodium channel Na(v)1.5 cause various cardiac arrhythmias.

76 lucinogenic potential and tendency to induce cardiac arrhythmias.

77 Among the most serious of these are cardiac arrhythmias.

78 roperty that is often defective in inherited cardiac arrhythmias.

79 ediator of severe hypoglycemia-induced fatal cardiac arrhythmias.

80 rica is experiencing an increasing burden of cardiac arrhythmias.

81 me beta3 mutations predispose individuals to cardiac arrhythmias.

82 potential oscillations and a known cause of cardiac arrhythmias.

83 is associated with systolic dysfunction and cardiac arrhythmias.

84 k factor for early after depolarizations and cardiac arrhythmias.

85 al remodeling resulting in increased risk of cardiac arrhythmias.

86 lene for therapies against heart failure and cardiac arrhythmias.

87 the placebo group in rates of hypotension or cardiac arrhythmias.

88 ion potential and potentially trigger lethal cardiac arrhythmias.

89 yed afterdepolarizations (DADs) that trigger cardiac arrhythmias.

90 -mediated severe hypoglycemia induces lethal cardiac arrhythmias.

91 5% confidence interval (CI): 0.54, 3.44) and cardiac arrhythmia (1.65%, 95% CI: 0.37, 2.95) increased

92 re; odds ratio, 2.48; 95% CI, 1.62 to 3.79), cardiac arrhythmia (11.5%, vs. 5.6% among those without

93 41 [3.2%] vs 33 [2.5%]) and supraventricular cardiac arrhythmia (12 [0.9%] vs 13 [1.0%]).

94 ency heart rate variability (LF/HFHRV )] and cardiac arrhythmias (196.0 +/- 239.9 vs. 19.8 +/- 21.7 e

95 vs. hypercapnia, respectively), incidence of cardiac arrhythmias (196.0 +/- 239.9 vs. 576.7 +/- 472.9

96 3.0% vs 42.7%; OR, 1.01; 95% CI, 0.98-1.05), cardiac arrhythmias (25.8% vs 26.0%; OR, 0.99; 95% CI, 0

97 Adverse event rates included cardiac arrhythmias (27.9% vs 25.2% of patients), cardia

98 9%; P=0.006) and an increase in frequency of cardiac arrhythmia (40.4% versus 31.4%; P=0.05).

99 events (14 vs 4, respectively; P = .02) and cardiac arrhythmias (57 vs 30; P = .004).

100 ation of betaARs increases the likelihood of cardiac arrhythmias, adverse ventricular remodelling, de

101 V-infected persons; however, the most common cardiac arrhythmia, AF, has not been adequately studied

102 brillation (AFib) is the most common type of cardiac arrhythmia, affecting 2.7 million to 6.1 million

103 the most common progressive and age-related cardiac arrhythmia, affects millions of people worldwide

104 Oxidative stress has been implicated in cardiac arrhythmia, although a causal relationship remai

105 no difference in the incidence of new major cardiac arrhythmia among the patients who received hydro

106 Atrial fibrillation (AF) is a common cardiac arrhythmia and a major risk factor for stroke, h

107 inical practice related to the management of cardiac arrhythmia and advanced heart failure syndromes.

108 rial fibrillation (AF) is a highly prevalent cardiac arrhythmia and cause of significant morbidity an

109 Atrial fibrillation is the most common cardiac arrhythmia and conveys a significant risk of mor

110 cases have clinically relevant mutations in cardiac arrhythmia and epilepsy genes.

111 we experimentally validate that an approved cardiac arrhythmia and heart failure drug, ouabain, show

112 several cardiovascular disorders, including cardiac arrhythmia and heart failure.

113 in uterine artery blood flow associated with cardiac arrhythmia and high magnitude irregular fluctuat

114 lasma metabolite trimethylamine-N-oxide with cardiac arrhythmia and infarction in CKD stage 3 patient

115 brillation (AF) is the most common sustained cardiac arrhythmia and is a major cause of stroke and mo

116 Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with a 5-fold incre

117 al fibrillation is the most common sustained cardiac arrhythmia and is associated with considerable m

118 Atrial fibrillation is the most common cardiac arrhythmia and leads to stroke.

119 gene causing a very rare autosomal recessive cardiac arrhythmia and LGMD, expanding the genetic cause

120 hole-exome sequencing, in a family of 4 with cardiac arrhythmia and limb-girdle muscular dystrophy (L

121 rited long QT syndrome and increased risk of cardiac arrhythmia and sudden death.

122 cated in human disease, including hereditary cardiac arrhythmia and type 2 diabetes (T2D).

123 mal cardiac electrophysiology and to prevent cardiac arrhythmias and AF.

124 azepines are used primarily for treatment of cardiac arrhythmias and are thought to physically block

125 nically reported as a risk factor for lethal cardiac arrhythmias and arrhythmic death.

126 treated, life-threatening complications like cardiac arrhythmias and broncholaryngospasm may occur.

127 a large number of mutations associated with cardiac arrhythmias and cardiomyopathies.

128 us comorbidities, eg, chronic heart failure, cardiac arrhythmias and chronic renal failure.

129 Death was associated with spontaneous cardiac arrhythmias and complete conduction block.

130 beta-Adrenergic blockade markedly reduced cardiac arrhythmias and completely abrogated deaths due

131 Cardiac arrhythmias and conduction disturbances are acco

132 erlies diverse ion channelopathies including cardiac arrhythmias and cystic fibrosis.

133 th arrhythmogenic cardiomyopathy who exhibit cardiac arrhythmias and dysfunction, palmoplanter kerato

134 ongenital channelopathies, such as deafness, cardiac arrhythmias and epilepsy.

135 behavior, thus leading to the development of cardiac arrhythmias and heart failure.

136 the development and pathophysiology of some cardiac arrhythmias and importantly, increase our unders

137 lay an important role in the pathogenesis of cardiac arrhythmias and may also contribute to the devel

138 We also describe the impact of COVID-19 on cardiac arrhythmias and methods of triage based on acuit

139 channels and abnormal sodium homeostasis in cardiac arrhythmias and pharmacotherapy from the subcell

140 moglein-2, which have been reported to cause cardiac arrhythmias and reduced conduction.

141 CMP and non-PPCMP patients except for higher cardiac arrhythmias and respiratory failure in the non-P

142 E inhibition and at higher concentrations to cardiac arrhythmias and seizures due to adenosine A1-rec

143 s study investigates the association between cardiac arrhythmias and short-term exposures to fine par

144 CaT) amplitude, is a high risk indicator for cardiac arrhythmias and sudden cardiac death.

145 CaT) amplitude--is a high risk indicator for cardiac arrhythmias and sudden cardiac death.

146 tance and coupling, and is a risk factor for cardiac arrhythmias and sudden cardiac death.

147 g QT syndrome (LQTS) and are associated with cardiac arrhythmias and sudden death.

148 fentanyl, potentially increasing the risk of cardiac arrhythmias and sudden death.

149 al fibrosis, and could influence the risk of cardiac arrhythmias and sudden death.

150 s on the ECG and increased susceptibility to cardiac arrhythmias and sudden death.

151 y syndrome, a rare disorder characterized by cardiac arrhythmias and syndactyly, highlighted roles fo

152 drome (TS), a rare disorder characterized by cardiac arrhythmias and syndactyly, highlighted unexpect

153 hough it has been reported to play a role in cardiac arrhythmias and to be upregulated in cardiac dis

154 e impact it has already had on the fields of cardiac arrhythmias and whole-heart computational modeli

155 ranulomatous therapy and pharmacotherapy for cardiac arrhythmias and/or heart failure in addition to

156 July 2013 on the combination of two terms: 'cardiac arrhythmias' and 'epilepsy'.

157 rt failure, peripheral vascular disease, and cardiac arrhythmia) and neuropsychiatric (depression and

158 de because of transient central line-induced cardiac arrhythmia, and another received only 6 of 10 pl

159 to variation within known AF susceptibility, cardiac arrhythmia, and cardiomyopathy gene regions.

160 symptoms include seizures, lactic acidosis, cardiac arrhythmia, and death within days of birth.

161 s, corneal opacities, testicular maldescent, cardiac arrhythmia, and higher rates of developmental an

162 ts included recurrent myocardial infarction, cardiac arrhythmia, and myocardial infarct size assessed

163 ons contribute to diseases such as epilepsy, cardiac arrhythmia, and neuromuscular symptoms collectiv

164 Cardiogenic and septic shock, cardiac arrhythmia, and postsurgical complication were t

165 l cellular and tissue events associated with cardiac arrhythmias, and the molecular genetics of monog

166 Exome data from 22 cardiac arrhythmia- and 41 cardiomyopathy-associated gen

167 Many cardiac arrhythmias are caused by slowed conduction of a

168 Cardiac arrhythmias are common in Fabry disease (FD) and

169 creased amounts of circulating cytokines and cardiac arrhythmias are demonstrated along with a freque

170 Seizure-related cardiac arrhythmias are frequently reported and have bee

171 ith cardiac arrhythmias, mechanisms by which cardiac arrhythmias are generated in such genetic mutati

172 The main inherited cardiac arrhythmias are long QT syndrome, short QT syndr

173 Cardiac arrhythmias are one of the most frequent causes

174 Life-threatening cardiac arrhythmias arise from asynchrony in these space

175 ion study identified atrial fibrillation and cardiac arrhythmias as the most common associated diagno

176 ttack, peripheral arterial complication, and cardiac arrhythmia), as well.

177 , and CKM; contractile fiber gene ACTA1; and cardiac arrhythmia associated ion channel coding genes A

178 contributing to the increased risk of fatal cardiac arrhythmias associated with diabetic cardiac aut

179 otential (AP) repolarization and can trigger cardiac arrhythmias associated with long QT syndrome.

180 Furthermore, V4880A, a cardiac arrhythmia-associated mutation, markedly enhance

181 d proportion of such patients diagnosed with cardiac arrhythmia attributable to the medications is 47

182 ome (TS) is a multisystem disorder featuring cardiac arrhythmias, autism and adrenal gland dysfunctio

183 drome (TS), a multisystem disorder featuring cardiac arrhythmias, autism spectrum disorder (ASD) and

184 lytic methodology for both heart failure and cardiac arrhythmias because the confidence intervals ove

185 uld, in principle, be used not only to treat cardiac arrhythmias but also to repair other organs.

186 ts the concept that autoantibodies may cause cardiac arrhythmias but substantial experimental investi

187 Atrial fibrillation (AF) is the most common cardiac arrhythmia, but little is known about the molecu

188 Atrial fibrillation (AF) is the most common cardiac arrhythmia, but our knowledge of the arrhythmoge

189 mutation of one of these is associated with cardiac arrhythmia (C981F), induces a significant enhanc

190 t, homeostasis and pathologic states such as cardiac arrhythmias, cancer and trauma.

191 exomes to identify participants at risk for cardiac arrhythmias, cardiomyopathies, or sudden death.

192 Many patients with cardiac arrhythmias caused by mutations in SCN5A also ha

193 ecular basis of the neurologic disorders and cardiac arrhythmias caused by NaV channel mutations.

194 ase, coronary artery disease, heart failure, cardiac arrhythmia, cerebrovascular disease, congenital

195 ventricular tachycardia (CPVT), an inherited cardiac arrhythmia characterized by adrenergically trigg

196 nce/absence of hypertension, hyperlipidemia, cardiac arrhythmias, coronary artery disease, congestive

197 erous diseases including neuronal disorders, cardiac arrhythmia, diabetes, and asthma.

198 utations in common genes responsible for the cardiac arrhythmia disease, long QT syndrome (LQTS).

199 Long-QT syndrome (LQTS), a cardiac arrhythmia disorder with variable phenotype, oft

200 oratories experienced in genetic testing for cardiac arrhythmia disorders, there was low concordance

201 afterdepolarizations (EADs) are triggers of cardiac arrhythmia driven by L-type Ca(2+) current (ICaL

202 There were no increases in any cardiac arrhythmia during or after exposure to dilute di

203 We investigated the incidence of cardiac arrhythmias during and after controlled exposure

204 tic nervous system (PSNS) in mediating fatal cardiac arrhythmias during insulin-induced severe hypogl

205 As a cellular precursor of lethal cardiac arrhythmias, early afterdepolarizations (EADs) d

206 mes included life-threatening hypotension or cardiac arrhythmia, endotracheal intubation, seizure rec

207 retome; improved cardiac function; abrogated cardiac arrhythmias, fibrosis, and apoptosis; and prolon

208 ssion and function that precede the onset of cardiac arrhythmia first observed at larval stages.

209 the large majority of subjects experiencing cardiac arrhythmias from macrolides have coexisting risk

210 ad candidate pathogenic variants in dominant cardiac arrhythmia genes.

211 rmed among 25 AF patients in a comprehensive cardiac arrhythmia genetic panel.

212 alvular atrial fibrillation, the most common cardiac arrhythmia globally.

213 Chronic heart failure and cardiac arrhythmias have high morbidity and mortality, a

214 rt failure and channelopathies that underlie cardiac arrhythmias, have been elucidated.

215 Cardiac arrhythmias, heart failure, and nonfatal coronar

216 0- and 90-day all-cause mortality and 90-day cardiac arrhythmias, heart failure, myocardial infarctio

217 In preventing cardiac arrhythmias, however, this goal may not be as im

218 tentials; these depolarized potentials cause cardiac arrhythmia; however, the underlying mechanism is

219 ry disease (HR: 1.89; 95% CI: 1.26 to 2.82), cardiac arrhythmias (HR: 1.62; 95% CI: 1.28 to 2.05), ch

220 We examined relationships between cardiac arrhythmias, HRV, and exposures to airborne part

221 Cardiac arrhythmias (i.e. inappropriate sinus tachycardi

222 ified seven distinct patterns of (post)ictal cardiac arrhythmias: ictal asystole (103 cases), postict

223 al fibrillation is the most common sustained cardiac arrhythmia in adults.

224 brillation (AF) is the most common sustained cardiac arrhythmia in clinical practice and is known to

225 r the observed genetic link between Cav1 and cardiac arrhythmias in humans and suggest that targeted

226 Atropine treatment reduced cardiac arrhythmias in mutant mice, implicating overacti

227 he findings offer a cellular basis for early cardiac arrhythmias in patients with arrhythmogenic card

228 beta-blockers prevent cardiac arrhythmias in patients with chronic heart failu

229 uniquely effective drug for the treatment of cardiac arrhythmias in patients with heart failure.

230 tochasticity is likely to reduce the risk of cardiac arrhythmias in patients.

231 ance and markedly increases the incidence of cardiac arrhythmias in rats with HFpEF.

232 regulation of the CSPG4 locus led to lethal cardiac arrhythmias in the absence of cardiac dysfunctio

233 t may primarily contribute to the genesis of cardiac arrhythmias in Timothy Syndrome.

234 Severe hypoglycemia caused numerous cardiac arrhythmias including premature ventricular cont

235 Alternans is a risk factor for cardiac arrhythmia, including atrial fibrillation.

236 ernans is a well-established risk factor for cardiac arrhythmia, including atrial fibrillation.

237 amplitude, and represents a risk factor for cardiac arrhythmia, including atrial fibrillation.

238 tudies are often used to study mechanisms of cardiac arrhythmias, including atrial fibrillation (AF).

239 el beta2-subunits, are associated with human cardiac arrhythmias, including atrial fibrillation and B

240 annel Na(V)1.5, are associated with multiple cardiac arrhythmias, including Brugada syndrome.

241 ensing protein calmodulin (CaM) cause severe cardiac arrhythmias, including catecholaminergic polymor

242 (2+) signaling is implicated in a variety of cardiac arrhythmias, including catecholaminergic polymor

243 Most genes underlying inherited cardiac arrhythmias, including KCNE3, are not exclusivel

244 Cardiac arrhythmia is a leading cause of death, often re

245 Atrial fibrillation, the most common cardiac arrhythmia, is an important contributor to morta

246 fibrillation (AF), the most common sustained cardiac arrhythmia, is associated with substantial morbi

247 ican countries provide complete services for cardiac arrhythmias, leaving more than hundreds of milli

248 roteins, including the cardiac-expressed and cardiac arrhythmia-linked transmembrane KCNE subunits.

249 ations were well identified in patients with cardiac arrhythmias, mechanisms by which cardiac arrhyth

250 ic receptor (beta-AR) activation can provoke cardiac arrhythmias mediated by cAMP-dependent alteratio

251 l utility is limited by side effects such as cardiac arrhythmias mediated by G protein signaling.

252 n chronic episodic disorders such as asthma, cardiac arrhythmias, migraine, epilepsy, and depression.

253 s with COVID-19 who die experience malignant cardiac arrhythmias more often than those surviving to d

254 Associations of cardiac arrhythmia, myocardial ischemia, myocardial infa

255 el pathway that underlies the development of cardiac arrhythmia, namely NOX4 activation, subsequent N

256 n found in families suffering from inherited cardiac arrhythmias, notably heart block.

257 Most cardiac arrhythmias occur intermittently.

258 Cardiac arrhythmias occurred early and in the absence of

259 Unexpectedly, cardiac arrhythmias occurred in >73% of deep, aerobic di

260 of PPV is unreliable (spontaneous breathing, cardiac arrhythmias) or doubtful (low Vt).

261 ses a significant (4- to 5-fold) increase in cardiac arrhythmias (P<0.001) that worsened with age and

262 Phase analysis of cardiac arrhythmias, particularly atrial fibrillation, h

263 te variability, and may increase the risk of cardiac arrhythmias, particularly in susceptible patient

264 mon cardiovascular complications were shock, cardiac arrhythmias, pericardial effusion, and coronary

265 mmittee paused the trial to evaluate safety (cardiac arrhythmia, persistent acidosis, major vessel th

266 rial fibrillation, the most common sustained cardiac arrhythmia, remain poorly understood.

267 ucidating the underlying mechanisms of fatal cardiac arrhythmias requires a tight integration of elec

268 Additionally, cardiac arrhythmia, respiratory control, and epilepsy ge

269 iac-Sirt1-deficient mice recapitulated human cardiac arrhythmias resulting from loss of function of N

270 Genetic predisposition to life-threatening cardiac arrhythmias such as congenital long-QT syndrome

271 rdiac rhythms, which have been implicated in cardiac arrhythmias such as T-wave alternans and various

272 e regional ischemia in the heart can lead to cardiac arrhythmias such as ventricular fibrillation (VF

273 in human Kv7.1 and KCNE1 genes, which cause cardiac arrhythmias, such as the long-QT syndrome (LQT)

274 cantly reduces the incidence and severity of cardiac arrhythmia, suggesting that metabolic dysfunctio

275 lators in cardiovascular disorders including cardiac arrhythmia susceptibility, cardiac conduction ph

276 exertional angina, acute coronary syndromes, cardiac arrhythmias, syncope, or even sudden cardiac dea

277 val fibromatosis is an allelic disorder with cardiac arrhythmia syndromes caused by KCNQ1 mutations.

278 ed gene defects can cause potentially lethal cardiac arrhythmia syndromes, including catecholaminergi

279 peutic approach to treating life-threatening cardiac arrhythmia syndromes.

280 Atrial fibrillation (AF) is a cardiac arrhythmia that arises from electrical and contr

281 Intriguingly, NOX4 embryos developed cardiac arrhythmia that is characterized by irregular he

282 ion (AF)- and Brugada syndrome (BrS)-induced cardiac arrhythmias that can arise from increased potass

283 lation (AF) is the most commonly encountered cardiac arrhythmia, the basic mechanisms underlying this

284 ion produces Long QT syndrome and the lethal cardiac arrhythmia torsade de pointes.

285 severe hypoglycemia were mediated by lethal cardiac arrhythmias triggered by brain neuroglycopenia a

286 aftercontractions and increased incidence of cardiac arrhythmias under stress conditions.

287 Because cardiac arrhythmias underlie most cardiac arrests and in

288 The incidence of cardiac arrhythmias was recorded for each exposure and s

289 A similar noninvasive treatment modality for cardiac arrhythmias was tested here.

290 minant myoclonus-dystonia-like syndrome with cardiac arrhythmias, we identified a mutation in the CAC

291 In summary, severe hypoglycemia-induced cardiac arrhythmias were increased by insulin deficiency

292 ion of left ventricle ejection fraction, and cardiac arrhythmias were reduced.

293 thm of a human heart may result in different cardiac arrhythmias, which may be immediately fatal or c

294 advances have enabled noninvasive mapping of cardiac arrhythmias with electrocardiographic imaging an

295 ne (AMD) acts on hERG K(+) channels to treat cardiac arrhythmias with relatively little arrhythmogeni

296 bles comprehensive noninvasive assessment of cardiac arrhythmias, with potential applications for dia

297 ventricular tachycardia that feature lethal cardiac arrhythmias without structural abnormality.

298 atrial cardiac rhythm, is the most prevalent cardiac arrhythmia worldwide.

299 of hERG channels is critical for preventing cardiac arrhythmia yet the mechanistic basis for the slo

300 brillation (AF) is the most common sustained cardiac arrhythmia, yet current pharmacological treatmen